Suriano C, Kumar N, Verpeut J, Ma J, Jung C, Dunn C
Mol Ther. 2024; 32(6):1721-1738.
PMID: 38566414
PMC: 11184335.
DOI: 10.1016/j.ymthe.2024.03.036.
Yi J, Lin P, Li Q, Zhang A, Kong X
Mol Ther Oncolytics. 2023; 30:254-274.
PMID: 37701850
PMC: 10493895.
DOI: 10.1016/j.omto.2023.08.010.
Lopes A, Hillen M, Hinrichs A, Blokland S, Bekker C, Pandit A
Ann Rheum Dis. 2022; 82(3):374-383.
PMID: 36171070
PMC: 9933176.
DOI: 10.1136/ard-2022-222728.
Blair T, Alice A, Zebertavage L, Crittenden M, Gough M
Front Oncol. 2021; 11:653625.
PMID: 33968757
PMC: 8101411.
DOI: 10.3389/fonc.2021.653625.
Weilhammer D, Dunkle A, Boone T, Gilmore S, Khemmani M, Peters S
Front Immunol. 2020; 11:1264.
PMID: 32714323
PMC: 7344197.
DOI: 10.3389/fimmu.2020.01264.
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.
Shen K, Liu H, Yan W, Wu C, Lee M, Leng C
Cancers (Basel). 2020; 12(4).
PMID: 32231003
PMC: 7225995.
DOI: 10.3390/cancers12040810.
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.
Shi Y, Zheng W, Yang K, Harris K, Ni K, Xue L
J Exp Med. 2020; 217(5).
PMID: 32142585
PMC: 7201921.
DOI: 10.1084/jem.20192282.
Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4 T Cell-Independent CD8 T-Cell Response Against Unconjugated Protein Antigen.
Chiodetti A, Sanchez Vallecillo M, Dolina J, Crespo M, Marin C, Schoenberger S
Front Immunol. 2018; 9:2319.
PMID: 30364187
PMC: 6192457.
DOI: 10.3389/fimmu.2018.02319.
Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
Schmidt S, Pedersen G, Neustrup M, Korsholm K, Rades T, Andersen P
Front Immunol. 2018; 9:898.
PMID: 29760705
PMC: 5936752.
DOI: 10.3389/fimmu.2018.00898.
A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis.
Dey B, Dey R, Cheung L, Pokkali S, Guo H, Lee J
Nat Med. 2015; 21(4):401-6.
PMID: 25730264
PMC: 4390473.
DOI: 10.1038/nm.3813.
Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
Song L, Yang M, Knoff J, Wu T, Hung C
PLoS One. 2014; 9(12):e115711.
PMID: 25531529
PMC: 4274108.
DOI: 10.1371/journal.pone.0115711.
Crosstalk between Mycobacterium tuberculosis and the host cell.
Dey B, Bishai W
Semin Immunol. 2014; 26(6):486-96.
PMID: 25303934
PMC: 4250340.
DOI: 10.1016/j.smim.2014.09.002.
Type I interferons as regulators of human antigen presenting cell functions.
Gessani S, Conti L, Del Corno M, Belardelli F
Toxins (Basel). 2014; 6(6):1696-723.
PMID: 24866026
PMC: 4073125.
DOI: 10.3390/toxins6061696.
Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.
Quinn K, Yamamoto A, Costa A, Darrah P, Lindsay R, Hegde S
J Immunol. 2013; 191(10):5085-96.
PMID: 24089189
PMC: 4100557.
DOI: 10.4049/jimmunol.1301730.
A novel post-transcriptional role for ubiquitin in the differential regulation of MHC class I allotypes.
Cano F, Lehner P
Mol Immunol. 2012; 55(2):135-8.
PMID: 23140835
PMC: 3625108.
DOI: 10.1016/j.molimm.2012.10.015.
Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.
Simmons D, Wearsch P, Canaday D, Meyerson H, Liu Y, Wang Y
J Immunol. 2012; 188(7):3116-26.
PMID: 22371391
PMC: 3311734.
DOI: 10.4049/jimmunol.1101313.
Effects of CpG-ODNs on phenotype and function of monocyte-derived dendritic cells in chronic hepatitis B.
Xiang X, Zhou X, Wang J, Xie Q, Cai X, Yu H
World J Gastroenterol. 2011; 17(43):4825-30.
PMID: 22147985
PMC: 3229633.
DOI: 10.3748/wjg.v17.i43.4825.
Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X, Li H, Matte-Martone C, Cui W, Li N, Tan H
Blood. 2011; 118(24):6426-37.
PMID: 21963602
PMC: 3236124.
DOI: 10.1182/blood-2011-06-358747.
Presentation of type B peptide-MHC complexes from hen egg white lysozyme by TLR ligands and type I IFNs independent of H2-DM regulation.
Strong B, Unanue E
J Immunol. 2011; 187(5):2193-201.
PMID: 21788443
PMC: 3509772.
DOI: 10.4049/jimmunol.1100152.
Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.
Simmons D, Canaday D, Liu Y, Li Q, Huang A, Boom W
J Immunol. 2010; 185(4):2405-15.
PMID: 20660347
PMC: 2990778.
DOI: 10.4049/jimmunol.0904005.